{"denoms":[{"counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"70"}],"units":"Participants"}],"groups":[{"description":"Epacadostat (Epa) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.","id":"BG000","title":"Group A: Epa + Pembrolizumab + mFOLFOX6"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.","id":"BG001","title":"Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.","id":"BG002","title":"Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"BG003","title":"Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent"},{"description":"Epa (100 mg)oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.","id":"BG004","title":"Group E: Epa + Pembrolizumab + Cyclophosphamide"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"BG005","title":"Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent"},{"description":"Epa (100 mg) oral BID continuousdaily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"BG006","title":"Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.03","value":"55.8"},{"groupId":"BG001","spread":"14.98","value":"46.0"},{"groupId":"BG002","spread":"12.11","value":"63.7"},{"groupId":"BG003","spread":"12.96","value":"58.2"},{"groupId":"BG004","spread":"10.21","value":"62.0"},{"groupId":"BG005","spread":"12.01","value":"60.3"},{"groupId":"BG006","spread":"12.24","value":"59.4"},{"groupId":"BG007","spread":"12.54","value":"58.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"36"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"34"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"55"}],"title":"White/Caucasian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"6"}],"title":"Black/African-American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}],"title":"Native Hawaiian/Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"5"}],"title":"Other"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"67"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}],"title":"Unknown"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The safety population included all participants enrolled in the study who received at least 1 dose of epacadostat, pembrolizumab, or an applicable chemotherapy regimen."}